Jentadueto 2.5 mg/850 mg film-coated tablets and Jentadueto 2.5 mg/1,000 mg film-coated tablets

  • Name:

    Jentadueto 2.5 mg/850 mg film-coated tablets and Jentadueto 2.5 mg/1,000 mg film-coated tablets

  • Company:
    info
  • Active Ingredients:

    Linagliptin, Metformin Hydrochloride

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 08/08/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 7/8/2019

Click on this link to Download PDF directly

Boehringer Ingelheim Limited

Boehringer Ingelheim Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Actilyse Active Ingredients Alteplase
Medicine Name Actilyse Cathflo 2 mg Active Ingredients Alteplase
Medicine Name APTIVUS 100 mg/ml oral solution Active Ingredients Tipranavir
Medicine Name Aptivus 250 mg soft capsules Active Ingredients Tipranavir
Medicine Name Atrovent 250 UDVs, 250 micrograms/1ml Nebuliser Solution Active Ingredients ipratropium bromide monohydrate
Medicine Name Atrovent 500 UDVs, 500 micrograms/2ml Nebuliser Solution Active Ingredients ipratropium bromide monohydrate
Medicine Name Atrovent Inhaler CFC-Free Active Ingredients ipratropium bromide monohydrate
Medicine Name Catapres Ampoules Active Ingredients Clonidine hydrochloride
Medicine Name Catapres Tablets 100 micrograms Active Ingredients Clonidine hydrochloride
Medicine Name Giotrif 20 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Giotrif 30 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Giotrif 40 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Giotrif 50 mg film-coated tablets Active Ingredients Afatinib dimaleate
Medicine Name Glyxambi 10 mg/5 mg film-coated tablets Active Ingredients Empagliflozin, Linagliptin
Medicine Name Glyxambi 25 mg/5 mg film-coated tablets Active Ingredients Empagliflozin, Linagliptin
Medicine Name Jardiance 10 mg and 25 mg Film-Coated Tablets Active Ingredients Empagliflozin
Medicine Name Jentadueto 2.5 mg/850 mg film-coated tablets and Jentadueto 2.5 mg/1,000 mg film-coated tablets Active Ingredients Linagliptin, Metformin Hydrochloride
Medicine Name Metalyse 10,000 units Active Ingredients Tenecteplase
Medicine Name Metalyse 8,000 units Active Ingredients Tenecteplase
Medicine Name Micardis 20 mg Tablets Active Ingredients Telmisartan
Medicine Name Micardis 40 mg Tablets Active Ingredients Telmisartan
Medicine Name Micardis 80 mg Tablets Active Ingredients Telmisartan
Medicine Name MicardisPlus 40 mg/12.5 mg tablets Active Ingredients Hydrochlorothiazide, Telmisartan
Medicine Name MicardisPlus 80 mg/12.5 mg tablets Active Ingredients Hydrochlorothiazide, Telmisartan
Medicine Name MicardisPlus 80 mg/25 mg Active Ingredients Hydrochlorothiazide, Telmisartan
1 - 0 of 48 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 8 August 2019 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 7 August 2019 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

  • Section 4.8: to merge ADR frequency columns + Update to Irish AE reporting information in line with Appendix V.
  • Section 5.1: Consequential administrative changes to section 4.8.
  • Section 10: Date of revision has been updated.

Updated on 7 May 2019 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 2 May 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SmPC has been updated in sections 4.4, 4.8, 5.1, 10 and minor format changes in section 4.4, 5.1

Updated on 30 July 2018 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 27 July 2018 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The only changes to the SmPC are:

Section 4.8 - Administrate update to the AE reporting details for the UK - inclusion of the reference to the Google Play/ Apple App Store.

Section 10 - Date of revision of the text has been aligned with the date of Positive Opinion

Updated on 8 September 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 8 September 2017 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 2 August 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 2 August 2017 SmPC

Reasons for updating

  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The changes are as follows:

-Sections 5.2: Details regarding the phase 2 PK/PD study in children and adolescents ≥10 to <18 years of age with type 2 diabetes mellitus has been added in the Paediatric population sub-section.

-Section 10: date of revision of the text, has also been aligned with the date of Positive Opinion, which was 22/06/2017.

Updated on 4 July 2017 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 3 July 2017 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Information on interaction of metformin with ionic cation transporters has been added to section 4.5 of the SPC. Section 10, date of revision of the text,

Updated on 10 May 2017 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 7 April 2017 PIL

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision
  • Removal of black triangle

Updated on 6 April 2017 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients
  • Change to section 6.5 - Nature and contents of container
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text
  • Correction of spelling/typing errors
  • Removal of black triangle

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.4 a warning relating to bullous pemphigoid has been added

Sections 4.2, 4.3, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2, 5.3, 6.1 and 6.5 have been revised due to the renewal procedure. Changes include:

The black triangle has been removed

Section 4.8 has been restructured

Minor editorial updates to most sections; sections 4.3 and 6.1 contain very minor typorgaphical corrections

Section 9 contains the renewal date

Updated on 23 February 2017 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Sections 4.1 (Therapeutic indications) and 5.1 (Pharmacodynamic properties) have been updated due to an Indication extension – Use of Jentadueto as add-on to a combination of metformin and empagliflozin

Section 4.4 (Special warnings and precautions for use) has been updated to remove the statement that Jentadueto should not be used for the treatment of diabetic ketoacidosis.

Section 4.5 (Interaction with other medicinal products and other forms of interaction) has been updated to clarify ‘combination requiring precautions for use’

Section 4.8 (Undesirable effects) has been updated with addition of the side effect ‘lipase increased’

 

In addition minor editorial changes were made to sections 4.8, 5.1 and 5.2.

Updated on 21 February 2017 PIL

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 10 January 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 6 January 2017 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.2 information on use of Jentadueto or individual components in patients with renal impairment was added.

In section 4.3 contraindications were updated to include any type of acute metabolic acidosis and severe renal failure. Contraindication in patients with renal dysfunction has been deleted.

In section 4.4 information on increased risk of lactic acidosis was added. The statement on renal function was revised to request GFR assessment prior to treatment and to temporarily discontinue treatment in conditions that alter renal function. Information on use of metformin and surgery was updated.

In section 5 statements on non-recommendation of concomitant use of alcohol and iodinated contract agents were revised. A statement on combinations requiring precautions for use was added.

Sections 4.8 and 5.1 were updated with minor editorial changes to table headings.

Section 10 was updated to include approval date

Updated on 31 May 2016 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 31 May 2016 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

To revise the ADR frequencies in section 4.8 of the SPC. Section 10, date of revision of the text has also been updated.

Updated on 11 March 2016 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 10 March 2016 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8 has been updated with addition of the side effect bullous pemphigoid with frequency not known. Section 10, date of revision of the text has also been updated.

Updated on 26 November 2015 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.1 - List of excipients
  • Change to section 8 - MA number
  • Change to section 10 - Date of revision of the text
  • Change to joint SPC covering all presentations

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.3 Contraindications – updated regarding disease which may cause tissue hypoxia (includes decompressed heart failure)

Section 4.4 Special warnings and precautions – Updated information on lactic acidosis - additional cautionary information relating to situations where renal function may become impaired; update to clarify when precaution should be taken and when the product is contraindicated in patients with reduced renal function and those with heart failure; update to information on use of iodinated contrast agent as this can lead to renal failure (consequential update to section 4.5)

In addition minor editorial corrections/updates have been made to sections 4.2, 4.4, 5.1 and 5.2.

Following a recent update of the European SPC template the two strengths of tablet have also been consolidated into one SPC. As a consequence sections 1, 2, 3, 6.1 and 8 have been revised.

Section 10, date of revision of the text has been updated

Updated on 20 November 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to instructions about overdose
  • Change to drug interactions
  • Change to date of revision
  • Change to MA holder contact details
  • Addition of information on reporting a side effect.

Updated on 10 December 2014 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision

Updated on 31 October 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 29 October 2014 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

These variations concerned the submission of updated Product information and RMP following CHMP recommendation of Art.5(3) procedure on GLP-1 based therapies and pancreatic issues (EMA/671092/2013) - class labelling. This affects section 4.4 of the SPCs.

 

In addition the adverse reporting information for Ireland in section 4.8 have been updated to reflect the current required details.

 

10. Date of revision

Updated to 09/2014

Updated on 28 August 2014 PIL

Reasons for updating

  • Change of manufacturer
  • Change to date of revision

Updated on 19 February 2014 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.1 Therapeutic indications
The following paragraph has been added to the section:

“Jentadueto is indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin and metformin alone do not provide adequate glycaemic control.”


4.2 Posology and method of administration
The following paragraph has been added to the section:

“For patients inadequately controlled on dual combination therapy with insulin and the maximal tolerated dose of metformin
The dose of Jentadueto should provide linagliptin dosed as 2.5 mg twice daily (5 mg total daily dose) and a dose of metformin similar to the dose already being taken. When linagliptin plus metformin hydrochloride is used in combination with insulin, a lower dose of insulin may be required to reduce the risk of hypoglycaemia (see section 4.4).”


4.4 Special warnings and precautions for use
This section has been updated as a consequence of the add-on to insulin

4.8 Undesirable effects
This section has been updated as a consequence of the add-on to insulin as well as other additional minor updates.


5.1 Pharmacodynamic properties

This section has been updated as a consequence of the add-on to insulin

10. Date of revision
Updated to 01/2014

Updated on 14 February 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about driving or using machinery
  • Change to how the medicine works
  • Change to date of revision

Updated on 27 September 2013 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision
  • Addition of information on reporting a side effect.
  • Addition of black triangle

Updated on 16 September 2013 SmPC

Reasons for updating

  • Addition of black triangle
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

- Black triangle and additional monitoring/adr reporting statement have been included preceding SPC section 1.
- Section 4.8 – statement relating to the reporting of suspected adverse reactions has been added and agency contact points added

minor changes have been made to section 4.2, 4.4, 5.1 and 5.2 to change ‘elderly’ to ‘older’
The wording of the associated paragraphs has been amendment to accommodate this change as required.

10. Date of revision
Updated to 08/2013

Updated on 14 May 2013 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8 – Table 1 has been updated

Section 5.1 – pharmacodynamic properties (update to the sub-section on cardiovascular meta-analysis plus other amendments).

Sections 4.5, 5.2 and 10 have also been updated – mainly editorial changes.

Updated on 14 May 2013 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 16 April 2013 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 5.1 - a typographical error has been corrected in Table 4

Section 6.3 - to increase the shelf life of the product from 2 to 3 years

Section 10 – date of revision have been updated to 03/2013

Updated on 10 October 2012 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 8 - MA number
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 6.5 – nature and contents of container of the SPCs along with section 8 – marketing authorisation numbers and section 10 – date of revision have been updated.

Updated on 4 October 2012 PIL

Reasons for updating

  • Change to date of revision
  • Introduction of new pack/pack size

Updated on 1 October 2012 PIL

Reasons for updating

  • New PIL for new product

Updated on 28 September 2012 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided